-
Uncategorized3 weeks ago
Combined biosynthesis and site-specific incorporation of phenylalanine derivatives from aryl aldehydes or carboxylic acids
Combined biosynthesis and site-specific incorporation of phenylalanine derivatives from aryl aldehydes or carboxylic acids
-
Uncategorized3 weeks ago
Parabilis Files for IPO, a Day After Signing Up-to-$2.3B Regeneron Collaboration
Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an...
-
Uncategorized3 weeks ago
FDA clears Gilead’s hepatitis D drug, four years after prior rejection
FDA clears Gilead's hepatitis D drug, four years after prior rejection
-
Uncategorized3 weeks ago
Enzymes Involved in Cholesterol Transport May Point to New Cancer Therapies
Enzymes Involved in Cholesterol Transport May Point to New Cancer Therapies
-
Uncategorized3 weeks ago
GOP lawmaker asks Trump administration to curb China biotech deals
GOP lawmaker asks Trump administration to curb China biotech deals
-
Uncategorized3 weeks agoSTAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further
Hospitals and other providers are bracing for an end to the extra money they’ve gotten for treating Medicaid patients, one of the many cuts contained in...
-
Uncategorized3 weeks ago
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
-
Uncategorized3 weeks ago
AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
AI Scientists, Stock Tumble, Patent Lawsuit, and New Partnerships
-
Uncategorized3 weeks agoASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
-
Uncategorized3 weeks ago
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
